Zdrowie i gospodarka · 15/05/2000

FDA Proposes Changes to Bacterial Vaccine Reclassification Based on Advisory Review Panel Findings

The FDA is proposing to reclassify certain bacterial vaccines and related biological products from Category IIIA to Category I or II based on advisory review panel findings, which will determine their safety, effectiveness, and labeling.